Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%

Core Insights - Mipletamig demonstrates an 86% clinical benefit rate in combination with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia (AML) patients, with no cases of cytokine release syndrome (CRS) reported [1][2] - The data indicates a strong efficacy profile and favorable safety, suggesting mipletamig could enhance current AML treatment standards, particularly for older or unfit patients [1][2] Clinical Data Highlights - Among 28 evaluable frontline patients, 100% remained free of CRS, with an 86% clinical benefit rate observed [1] - 79% of patients achieved complete remission (CR) or complete remission with incomplete blood marker recovery (CRi), with 61% achieving CR [1] - 55% of patients who achieved CR/CRi reached measurable residual disease-negative levels, indicating stronger responses [1] - 35% of patients with remissions had the TP53 genetic mutation, a high-risk biomarker associated with poor prognosis in AML [1] Company Overview - Aptevo Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer, utilizing proprietary ADAPTIR and ADAPTIR-FLEX platforms [2] - The company aims to improve treatment outcomes for cancer patients, with mipletamig being a key candidate for AML treatment [2]